<DOC>
	<DOCNO>NCT00246129</DOCNO>
	<brief_summary>The advent new , potent immunosuppressive ( anti-rejection ) drug past ten year substantially reduce risk rejection kidney transplantation , allow development immuno-suppressive regimen use long-term steroid ( steroid avoidance ) , improve transplant success rate short medium term . The main new agent use modern regimen calcineurin inhibitor tacrolimus ; anti-proliferative agent mycophenolate ; induction agent use provide effective early suppression rejection process ; include monoclonal antibody ( MoAb ) IL-2 receptor block antibody ( IL-2R MoAb : basiliximab daclizumab ) anti-CD52 antibody Campath-1H ( alemtuzumab ) . Although almost modern immunosuppressive regimen involve one agent , know safe effective combination . This randomise control trial compare two steroid spar regimen use good short medium term result St Mary 's Hospital Renal Transplant Unit last 5 year . The primary hypothesis alemtuzumab/tacrolimus regimen effective safe IL-2R MoAb/tacrolimus/mycophenolate regimen .</brief_summary>
	<brief_title>Comparison Alemtuzumab/Tacrolimus Versus Interleukin-2 Receptor ( IL-2R ) Monoclonal Antibody ( MoAb ) /Tacrolimus/Mycophenolate Kidney Transplantation</brief_title>
	<detailed_description>RECENT EXPERIENCE AT ST MARY 'S : The St Mary 's Hospital Renal Unit ( combine Hammersmith Hospital Renal Unit West London Renal Transplant Centre ) introduce Tacrolimus base immunosuppression 1995 , develop steroid avoidance regimen base Tacrolimus , Mycophenolate , IL-2R MoAb 2000 2002 , move Campath-1H induction agent 2004 . Results period excellent five ten year survival function graft rate 82 % 72 % first 260 cadaveric kidney transplant perform since 1995 . The two recent regimen use St Mary 's produce low ( &lt; 10 % ) rejection rate , good ( &gt; 90 % ) short−term rejection-free patient graft survival rate . Between 2002 2004 , regimen consist induction IL2-Receptor block monoclonal antibody Tacrolimus Mycophenolate long term maintenance therapy . In patient without rejection steroid usage limit first 7 day post−transplant . The current regimen us Campath-1H ( well establish induction agent renal transplantation induction ) , Tacrolimus monotherapy maintenance identical short-course steroid regimen . CHARACTERISTICS OF THE TWO REGIMENS TO BE COMPARED : The IL2R MoAb/Tacrolimus/Mycophenolate/Short−course steroid regimen ( 2002−2004 Regimen 1 ) advantage flexibility term adjust maintenance therapy allow clinical response patient transplant different tolerance two maintenance agent , involves increase expense term use monitor blood level two modern ( hence expensive ) agent . In addition , patient long−term exposure anti−proliferative agent Mycophenolate , associate increase risk infection , gastrointestinal side effect , skin malignancy . The Campath-1H/Tacrolimus/Short−course steroid regimen ( 2004−current , Regimen 2 ) advantage highly effective immunosuppression initial 3−month period , allow low dos potentially nephrotoxic Tacrolimus use , simplicity , expose patient period several month lymphopenia ( reduce lymphocyte count blood ) Campath administration , reliance Tacrolimus monotherapy maintenance might lead great long term Tacrolimus exposure . PROPOSED STUDY : In order allow proper comparison two anti−rejection treatment combination propose randomise trial enable u consider relative merit two regimen without introduction bias associate use historical control group . Transplant recipient randomise 1:2 ratio regimen 1 regimen 2 .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Kidney transplant recipient care West London Renal Transplant Centre Patients unable give write informed consent Simultaneous kidney/pancreas transplant recipient Non−heart beat decease donor transplant recipient Patients would offer Campath1H induction current protocol ( patient previous malignancy previous exposure cytotoxic antiproliferative agent )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Kidney Disease</keyword>
	<keyword>Kidney Failure</keyword>
	<keyword>Graft Rejection</keyword>
</DOC>